 |
5 Products |  |
33 Diseases | | 5 Products |
|
1369 Trials |  |
5508 News |  |
| «12...1415161718192021222324...4748» |
- ||| TQB2858 / Sino Biopharm
Enrollment open, IO biomarker, Metastases: A Clinical Trial to Evaluate Tolerability and Security of TQB2858 Injection in Subjects With Advanced Pancreatic Carcinoma (clinicaltrials.gov) - Nov 3, 2022
P1, N=104, Recruiting, Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Not yet recruiting --> Recruiting
- ||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
Enrollment closed, Monotherapy, Metastases: Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) (clinicaltrials.gov) - Nov 3, 2022
P3, N=325, Active, not recruiting, Sponsor: Advenchen Laboratories, LLC
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||| Tyvyt (sintilimab) / Eli Lilly, Focus V (anlotinib) / Advenchen, Sino Biopharm
2) #ASCO22 Abs#8516 interesting IO + TKI study in ES-SCLC presented by Dr. Ma, Sintilimab + Anlotinib in #LCSM ES-SCLC ➡️ORR: 48.7% ➡️mPFS: 6 mths ✅ 12 mth OS: 56% 😧 TRAE: 95% @OncoAlert https://t.co/DFcZ4t7ESE @HemOncFellows @OncBrothers #SCLCBriefs @SoMeCME (Twitter) - Nov 1, 2022
- || Focus V (anlotinib) / Advenchen, Sino Biopharm
Review, PD(L)-1 Biomarker, IO biomarker: Case Report: Anlotinib combined with PD-1 inhibitor and sequential GA regimen or FOLFIRINOX Chemotherapy in treatment of KRAS G12V mutated pancreatic ductal adenocarcinoma with liver metastasis: A case and literature review. (Pubmed Central) - Nov 1, 2022
Consequently, there is some hope for patients with pancreatic cancer, especially for KRAS G12V gene mutated patients. Upon reviewing the literature, this patient's combination therapy is the first to have been reported.
- | AiTan (rivoceranib) / HLB Bio Group, Avastin (bevacizumab) / Roche
Biomarker, Trial suspension: Biomarkers for Apatinib and Bevacizumab in Second-line Therapy for Colorectal Cancer(BABST-C) (clinicaltrials.gov) - Nov 1, 2022
P=N/A, N=40, Suspended, Sponsor: Shenzhen People's Hospital
Upon reviewing the literature, this patient's combination therapy is the first to have been reported. Recruiting --> Suspended
- | AiRuiKa (camrelizumab) / HLB Bio Group, Focus V (anlotinib) / Advenchen, Sino Biopharm
New trial, Combination therapy, Metastases: A Study of Camrelizumab in Combination With Anlotinib in Subjects Advanced Ovarian Clear Cell Carcinoma (clinicaltrials.gov) - Nov 1, 2022
P=N/A, N=20, Not yet recruiting, Sponsor: Peking University Third Hospital
- Irene (pyrotinib) / Jiangsu Hengrui Pharma, Focus V (anlotinib) / Advenchen, Sino Biopharm
A Phase Ib/II Study of anlotinib combined with pyrotinib and capecitabine for HER2-positive metastatic breast cancer (Hall 1) - Oct 28, 2022 - Abstract #SABCS2022SABCS_1984;
A sample size of 23 provided 80% power at 2-sided alpha = 0.20 to detect a minimum of 20% improvement (45% vs. 65%) in one-year PFS. The phase Ib portion of the trial is currently enrolling in China.
- | New P2 trial, Metastases: BCTOP-L-M05: SNF Platform Study of HR+/ HER2-advanced Breast Cancer (clinicaltrials.gov) - Oct 26, 2022
P2, N=140, Not yet recruiting, Sponsor: Fudan University
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal, Real-world evidence: A Real-World Study of Optimal Treatment with Anlotinib First-Line Therapy in Advanced Hepatocellular Carcinoma. (Pubmed Central) - Oct 25, 2022
Anlotinib is effective and well-tolerated as a first-line treatment for patients with aHCC. Treatment with TKIs and PD-1 inhibitors after disease progression has also shown preliminary efficacy and safety; therefore, sequential therapy with anlotinib-TKIs and PD-1 inhibitors may be an effective treatment for patients with aHCC.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal, Checkpoint inhibition, IO biomarker: Clinical Efficacy of Antianlotinib Combined with Immune Checkpoint Inhibitors in the Treatment of Advanced Non-Small-Cell Lung Cancer and Its Effect on Serum VEGF, CEA, and SCC-Ag. (Pubmed Central) - Oct 25, 2022
The combination of anlotinib with ICIs was more effective than either agent alone in the first- and second-line treatment of patients with advanced NSCLC. This treatment regimen did not interfere with immunological recovery or increase side effects.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal: Clinical Application of Anlotinib Combined with Docetaxel: Safe and Effective Treatment for Lung Carcinoma. (Pubmed Central) - Oct 25, 2022
These benefits make it worthy of a broader clinical application. Although pharmacological treatment was applied in this study based on the mechanism, specific bioeffective markers are yet to be identified, presenting a direction for future research.
- | AL8326 / Advenchen
Trial initiation date: Phase 2 Safety and Efficacy Evaluation of AL8326 in ?2nd Line SCLC (clinicaltrials.gov) - Oct 24, 2022
P2, N=36, Not yet recruiting, Sponsor: Advenchen Pharmaceuticals, LLC.
Although pharmacological treatment was applied in this study based on the mechanism, specific bioeffective markers are yet to be identified, presenting a direction for future research. Initiation date: Jul 2022 --> Nov 2022
- Focus V (anlotinib) / Advenchen, Sino Biopharm, APL-502 / Apollomics
TQB2450 plus anlotinib combined with paclitaxel and cisplatin as first-line treatment of advanced esophageal squamous cell carcinoma (ESCC): a single-arm, multicenter phase II trial (Foyer ABC) - Oct 21, 2022 - Abstract #ESMOIO2022ESMO_IO_317;
P2
AEs led to discontinuation of TQB2450 in 7.9% and anlotinib in 7.9% of enrolled patients. Conclusions TQB2450 plus anlotinib combined with paclitaxel and cisplatin showed significant efficacy and manageable toxicities as first-line treatment in advanced ESCC, which might provide a new treatment strategy for those.
- Tuoyi (toripalimab) / Shanghai Junshi Biosci, Coherus Biosci, Focus V (anlotinib) / Advenchen, Sino Biopharm
Stereotactic body radiotherapy plus anlotinib ± toripalimab in untreated oligometastatic brain metastases NSCLC patients (Foyer ABC) - Oct 21, 2022 - Abstract #ESMOIO2022ESMO_IO_299;
P1
The induction part combined immunotherapy increases manageable TRAEs incidence. Further efficacy and safety data require follow-up confirmation after enrollment.
- Opdivo (nivolumab) / Ono Pharma, BMS
Safety and efficacy of multi-target TKI combined with nivolumab in check-point inhibitor-refractory advanced NSCLC patients: a prospective, single arm, two stage study (Foyer ABC) - Oct 21, 2022 - Abstract #ESMOIO2022ESMO_IO_287;
P1/2
Conclusions Our study suggested that full dose anlotinib combined with nivolumab showed positive safety and efficacy signal. Further study is warranted.
- Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
Penpulimab (Anti-PD-1) combined with anlotinib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Updated overall survival results from a phase Ib/II study (Foyer mezzanine) - Oct 21, 2022 - Abstract #ESMOIO2022ESMO_IO_233;
P2, P3
Conclusions Anlotinib combined with penpulimab showed encouraging efficacy and acceptable safety in pts with uHCC. The further randomized, phase 3 study of penpulimab plus anlotinib at a higher dose (10 mg) in this setting is ongoing (NCT04344158).
- Focus V (anlotinib) / Advenchen, Sino Biopharm
A retrospective real-world study of anlotinib plus PD-1 inhibitors in advanced esophageal squamous cell carcinoma (ESCC) previously treated with immune checkpoint inhibitors (ICIs). (Foyer mezzanine) - Oct 21, 2022 - Abstract #ESMOIO2022ESMO_IO_223;
Conclusions Anlotinib plus PD-1 inhibitors showed encouraging anti-tumor activity and manageable safety in advanced ESCC previously treated with ICIs, providing a feasible and well-tolerated treatment option for this patient population. The data further need to be validated in prospective study.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Trial completion, Trial primary completion date, Real-world evidence, Real-world, Metastases: A Real-world Study: Efficacy and Safety of Anlotinib for Advanced Non-small Cell Lung Cancer(NSCLC) (clinicaltrials.gov) - Oct 21, 2022
P=N/A, N=373, Completed, Sponsor: Qian Chu
The data further need to be validated in prospective study. Recruiting --> Completed | Trial primary completion date: Jul 2021 --> Jul 2022
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal: Anlotinib Hydrochloride and PD-1 Blockade as a Salvage Second-Line Treatment in Patients with Progress of Local Advanced Non-Small Cell Lung Cancer in Half a Year After Standard Treatment. (Pubmed Central) - Oct 21, 2022
The expected outcome of this study is that anlotinib combined with PD-1 blockade has tolerable toxicity and better ORR, OS than second-line chemotherapy. The results may indicate additional treatment options for patients with progress of local advance NSCLC in half a year after standard treatment.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal, Combination therapy: Safety and efficacy of anlotinib in combination with standard chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A multi-center, prospective study (ACTION-2). (Pubmed Central) - Oct 21, 2022
P2
The results may indicate additional treatment options for patients with progress of local advance NSCLC in half a year after standard treatment. Given its promising efficacy, safety profile and durability, anlotinib combined with chemotherapy deserves further investigation as first-line anticancer therapy in ES-SCLC (NCT: 04684017).
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal, PD(L)-1 Biomarker, IO biomarker: Anlotinib Benefits the αPDL1 Immunotherapy by Activating ROS/JNK/AP-1 Pathway to Upregulate PDL1 Expression in Colorectal Cancer. (Pubmed Central) - Oct 21, 2022
On one hand, the ROS/JNK/AP-1 pathway needs to be proved whether it can be activated in human cell lines. On the other hand, the mechanism behind ROS promoting phosphorylation of JNK needs to be explored.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
A multicenter, randomized, double-blind, phase III study of gefitinib in combination with anlotinib or placebo in previously untreated patients with EGFR mutation-positive advanced non-small cell lung cancer (FL-ALTER) (Hall 406) - Oct 21, 2022 - Abstract #ESMOAsia2022ESMO_Asia_987;
P3
We will update the detailed biomarker data in congress. Conclusions Compared with G+P group, G+A group significantly prolonged PFS in pts with untreated metastatic EGFR-mutated NSCLC and the safety profiles were manageable.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal: Anlotinib inhibits the proliferation and induces apoptosis by inactivating the AKT pathway in androgen receptor-negative prostate cancer cells. (Pubmed Central) - Oct 19, 2022
In addition, molecular docking analysis revealed potential interactions between anlotinib and AKT1 at multiple sites. Overall, the present study suggested that anlotinib could inhibit the proliferation and induce apoptosis in the AR-negative prostate cancer cell lines, possibly via the inactivation of the AKT pathway.
- |||| Focus V (anlotinib) / Advenchen, Sino Biopharm, epirubicin / Generic mfg.
Clinical: Anlotinib plus epirubicin followed by anlotinib maintenance as first-line treatment for advanced soft tissue sarcoma: an open-label, single-arm, phase 2 trial https://t.co/gGjAczICC2 @CCR_AACR novel approach to Catequentinib/anlotinib for sarcoma (Twitter) - Oct 17, 2022
- | New P1/2 trial: FASCINATE-N: Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy (clinicaltrials.gov) - Oct 17, 2022
P1/2, N=716, Not yet recruiting, Sponsor: Fudan University
- || Avastin (bevacizumab) / Roche, Focus V (anlotinib) / Advenchen, Sino Biopharm
Review: Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab. (Pubmed Central) - Oct 15, 2022
Most adverse events (AEs) were grade one or two; the most common AEs were fatigue (51.7%), hypertension (41.3%), hand-foot syndrome (41.4%), anorexia (34.5%) and hypertriglyceridemia (34.5%). Anlotinib demonstrated favourable activity and manageable toxicity in NSCLC patients who were treated with bevacizumab previously.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal: Anlotinib plus platinum-etoposide as a first-line treatment for extensive-stage small cell lung cancer: A single-arm trial. (Pubmed Central) - Oct 14, 2022
Anlotinib demonstrated favourable activity and manageable toxicity in NSCLC patients who were treated with bevacizumab previously. Anlotinib combined with platinum-etoposide provided an effective and safe therapy for patients with ES-SCLC.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Biomarker, Retrospective data, Journal: Efficacy, safety, and prognostic factors of anlotinib treatment in advanced non-small cell lung cancer patients. (Pubmed Central) - Oct 14, 2022
Regarding safety, most of the adverse events were at mild grade. Anlotinib displays good efficacy and well-tolerant safety profiles in the treatment of advanced NSCLC patients.
- || Focus V (anlotinib) / Advenchen, Sino Biopharm
P2 data, Journal: Anlotinib plus epirubicin followed by anlotinib maintenance as first-line treatment for advanced soft tissue sarcoma: an open-label, single-arm, phase 2 trial. (Pubmed Central) - Oct 14, 2022
Anlotinib displays good efficacy and well-tolerant safety profiles in the treatment of advanced NSCLC patients. The combination of anlotinib and epirubicin followed by anlotinib maintenance demonstrated promising efficacy with a favorable safety profile.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal: SOD2 confers anlotinib resistance via regulation of mitochondrial damage in OSCC. (Pubmed Central) - Oct 14, 2022
SOD2 may be capable of protecting mitochondria by downregulating ROS generation, which contributes to the resistance of anlotinib in OSCC cells. SOD2 can be utilized as a potential therapeutic target to improve the anti-cancer efficacy of anlotinib in OSCC.
- ||||| Anniko (penpulimab) / Akesobio, Sino Biopharm
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Metastases: AK105-301: A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer (clinicaltrials.gov) - Oct 13, 2022
P3, N=164, Active, not recruiting, Sponsor: Akeso
SOD2 can be utilized as a potential therapeutic target to improve the anti-cancer efficacy of anlotinib in OSCC. Unknown status --> Active, not recruiting | N=360 --> 164 | Trial completion date: Nov 2021 --> Jun 2024 | Trial primary completion date: Nov 2020 --> Jun 2023
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal: The Combination of Anlotinib and Gemcitabine/Docetaxel in Patients with Metastatic Osteosarcoma Who Have Failed Standard Chemotherapy. (Pubmed Central) - Oct 12, 2022
The combination of anlotinib and GD showed favorable efficacy with manageable toxicities compared with GD in the second-line treatment for metastatic osteosarcoma. This combination therapy deserves further investigations in patients with osteosarcoma.
- | Anniko (penpulimab) / Akesobio, Sino Biopharm
Enrollment closed, Trial completion date, Trial primary completion date: AK105-203: A Study of the Combination of Anti-PD-1 AK105 and Anlotinib in First-line Hepatocellular Carcinoma (HCC) (clinicaltrials.gov) - Oct 12, 2022
P2, N=31, Active, not recruiting, Sponsor: Akeso
This combination therapy deserves further investigations in patients with osteosarcoma. Unknown status --> Active, not recruiting | Trial completion date: Jun 2021 --> Nov 2022 | Trial primary completion date: Jun 2020 --> Jun 2022
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Neoadjuvant anlotinib plus nab-paclitaxel based chemotherapy in patients with HER2-negative breast cancer: A prospective, single-arm, single-center, phase II clinical study (Hall 1) - Oct 10, 2022 - Abstract #SABCS2022SABCS_1748;
Thirty pts will be enrolled and received 5 cycles of anlotinib (12 mg qd, d1-14; 21 days per cycle) plus 6 cycles of nab-paclitaxel (200 mg/m2, once every 3 weeks), anthracycline ( pirarubicin 50 mg/m2) and cyclophosphamide at 500 mg/m2, followed by surgery. The trail is in progress.
- Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
A prospective phase 2 study on efficacy and safety of AK105, anlotinib combined with nab-paclitaxel (nab-P) as a first-line therapy in patients(pts) with advanced triple-negative breast cancer(TNBC) (Hall 1) - Oct 10, 2022 - Abstract #SABCS2022SABCS_1714;
P2
Simon’s two-stage design were used to calculate the sample size assuming ORR is improved from 45.9% (nab-P alone) to 65% (AK105, anlotinib combined with nab-P) with the power (1-β) taken as 0.80 and the type I error (α) taken as 0.05 (two-sided). Enrollment began in June 2022 with a total goal of 42 pts at 7 sites in China.
- Tyvyt (sintilimab) / Eli Lilly, Focus V (anlotinib) / Advenchen, Sino Biopharm
Efficacy and safety of sintilimab in combination with anlotinib plus metronomic chemotherapy in advanced triple negative breast cancer (SPACE): preliminary results of a single-arm, multicenter phase II trial (Hall 1) - Oct 10, 2022 - Abstract #SABCS2022SABCS_1646;
The clinical significance of ctDNA dynamic monitoring needs further validation. Clinical trial information: ChiCTR2100044725
- lobaplatin (D19466) / AEterna Zentaris, Focus V (anlotinib) / Advenchen, Sino Biopharm
Phase 2 study of anlotinib combined with taxanes and lobaplatin in the neoadjuvant treatment of triple-negative breast cancer: efficacy, safety and biomarker analysis from the SWH-B006 (neoALTALL) trial (Hall 1) - Oct 10, 2022 - Abstract #SABCS2022SABCS_1350;
The addition of anlotinib to neoadjuvant chemotherapy showed manageable toxicity and promising antitumor activity for pts with early-stage TNBC. The study is still ongoing, and the enrollment has been completed.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
A retrospective study of anlotinib in patients with HER-2 negative metastatic breast cancer after prior two or more lines treatment (Hall 1) - Oct 10, 2022 - Abstract #SABCS2022SABCS_965;
These patients received anlotinib combination with investigator-selected chemotherapy agents, including docetaxel, vinorelbine, gemcitabine, etoposide, alibrine and so on. Anlotinib is safe and effective in patients with HER-2 negative metastatic breast cancer after prior two or more lines treatments, and it is well tolerated.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
The efficacy of Anlotinib combined with TEC in neo-adjuvant treatment for triple-negative breast cancer and the value of multi-point core needle biopsy in prediction of pathologic complete remission: A retrospective analysis (Hall 1) - Oct 10, 2022 - Abstract #SABCS2022SABCS_514;
It is safe, reliable, feasible and accurate to evaluate the efficacy of neo-adjuvant therapy and to predict pathological complete response by multi-point core needle biopsy. It means that the clinical evaluation of neo-adjuvant therapy can transition from imaging evaluation to pathological evaluation, which is helpful for the choice of surgical methods.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
The activity and safety of anlotinib combined with chemotherapy for patients with desmoid tumor: A retrospective study in a single institution (Exhibition / Poster Area) - Oct 9, 2022 - Abstract #ESMOAsia2022ESMO_Asia_943;
Conclusions Anlotinib combine with chemotherapy was effective against DT with an acceptable safety profile, and significantly slowed the disease progression. Further, multicenter studies with a longer follow-up time are needed to characterize fully the clinical application of anlotinib combine with chemotherapy in DT.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
The activity and safety of anlotinib for patients with recurrent malignant glioma: A single-center, retrospective study (Exhibition / Poster Area) - Oct 9, 2022 - Abstract #ESMOAsia2022ESMO_Asia_909;
Conclusions Anlotinib was effective in terms of ORR, and DCR, and was well tolerated. Further randomized controlled clinical studies are needed to confirm the efficacy of Anlotinib for the treatment of rMG.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Efficacy of anlotinib in posterior line treatment of locally advanced and metastatic NSCLC with KRAS mutation (Exhibition / Poster Area) - Oct 9, 2022 - Abstract #ESMOAsia2022ESMO_Asia_879;
Unfortunately, although this study also included people who received immunotherapy (30 cases), the endpoint of the study was not reached due to the late initiation of drug use. The data of the immunotherapy group are expected to be updated and released in the future.
- Imfinzi (durvalumab) / AstraZeneca, Focus V (anlotinib) / Advenchen, Sino Biopharm
Efficacy and safety analysis of anlotinib and durvalumab plus chemotherapy in first-line therapy extensive-stage small cell lung cancer (SCLC) (Exhibition / Poster Area) - Oct 9, 2022 - Abstract #ESMOAsia2022ESMO_Asia_850;
No higher-grade adverse reactions. Conclusions Durvalumab plus anlotinib and chemotherapy regimen has better ORR, DCR and PFS for the initial treatment of extensive-stage SCLC, and a manageable safety profile.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Anlotinib plus standard chemotherapy as first-line treatment in extensive-stage small cell lung cancer patients (Exhibition / Poster Area) - Oct 9, 2022 - Abstract #ESMOAsia2022ESMO_Asia_849;
P2
Conclusions In view of the encouraging efficacy, safety profile and durability, anlotinib combined with chemotherapy may provide a potential and novel treatment option for ES-SCLC patients. The study results need further validated in a randomized trial.
- Avastin (bevacizumab) / Roche, iparomlimab/tuvonralimab (PSB205) / Sound Biologics
A phase II, open-label, single-center study of QL1706 plus platinum doublet chemotherapy with bevacizumab as first-line treatment in patients with advanced NSCLC: Data from EGFR mutant cohort (Exhibition / Poster Area) - Oct 9, 2022 - Abstract #ESMOAsia2022ESMO_Asia_826;
P2
Methods Eligible pts had a pathologically confirmed diagnosis of stage IV non-squamous NSCLC with EGFR-sensitizing mutation; had measurable disease; and had experienced disease progression or could not tolerate EGFR TKIs+bevacizumab/anlotinib...Pts received QL1706 (5.0 mg/kg), bevacizumab, pemetrexed, and carboplatin on day 1 of each 21-day cycle for 4 cycles in the induction treatment...Conclusions QL1706+platinum-based chemo+bevacizumab demonstrated promising clinical activity, with favorable tolerability in pts with EGFR mutant NSCLC and failed in EGFR TKI therapy. Further investigations in this setting are continuing.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Efficacy and safety analysis of anlotinib combined with immunotherapy as second-line therapy for advanced non-small cell lung cancer (NSCLC) (Exhibition / Poster Area) - Oct 9, 2022 - Abstract #ESMOAsia2022ESMO_Asia_819;
Conclusions Anlotinib plus immunotherapy as second-line therapy showed a promising efficacy with a favorable toxicity profile for patients with advanced non-small cell lung cancer. We will report more data in the future.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Real-world efficacy and safety of anlotinib in combination with PD-1/PD-L1 inhibitors as first-line or second-line treatment in advanced non-small cell lung cancer (Exhibition / Poster Area) - Oct 9, 2022 - Abstract #ESMOAsia2022ESMO_Asia_801;
Conclusions This real-word study finds that anlotinib combined with PD-1/PD-L1 inhibitors shows good efficacy and safety in NSCLC patients. The treatment effects are similar to the outcomes in comparable clinical trials, which support the further recommendation of anlotinib combined with PD-1 inhibitors in the treatment of NSCLC.
- Tyvyt (sintilimab) / Eli Lilly, Focus V (anlotinib) / Advenchen, Sino Biopharm
Sintilimab plus anlotinib as second-line therapy for metastatic or recurrent gallbladder carcinoma (GBC): A single-arm, phase II study (Exhibition / Poster Area) - Oct 9, 2022 - Abstract #ESMOAsia2022ESMO_Asia_639;
The most common TRAEs were hand-foot syndrome (30.8%), diarrhea (23.1%), hypothyroidism (23.1%), and oral mucositis (23.1%). Conclusions Given the encouraging ORR and tolerable safety, the regimen of sintilimab plus anlotinib may be a viable and safe option for second-line metastatic or recurrent GBC treatment.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal, Real-world evidence: The efficacy and safety of anlotinib combined with platinum-etoposide chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A Chinese multicenter real-world study. (Pubmed Central) - Oct 8, 2022
Anlotinib combined with platinum-etoposide chemotherapy as the first-line treatment for ES-SCLC appears to be effective and well-tolerated in the real-world. Well-designed large-scale prospective studies are urgently needed in the future to verify our findings.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal: Effectiveness and Tolerability of Anlotinib Plus PD-1 Inhibitors for Patients with Previously Treated Metastatic Soft-Tissue Sarcoma. (Pubmed Central) - Oct 6, 2022
Anlotinib plus PD-1 inhibitors demonstrated durable and promising efficacy and tolerable safety for patients with metastatic STS in real world. Further prospective clinical trials were warranted to validate the feasibility of anlotinib plus PD-1 blockades clinically.